Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Elite Pharmaceuticals Inc. (ELTP : OTC)

• Company Description    Elite Pharmaceuticals, Inc. primarily engages in researching, developing, licensing, manufacturing, and marketing proprietary drug delivery systems and products. Their drug delivery technology involves releasing a drug into the bloodstream or delivering it to a target site in the body over an extended period of time or at predetermined times. Number of Employees: 68

• Price / Volume Information    Yesterday's Closing Price: $0.35 Daily Weekly Monthly 20 Day Moving Average: 578,749 shares Shares Outstanding: 1,077.14 (millions) Market Capitalization: $372.15 (millions) Beta: 0.40 52 Week High: $0.82 52 Week Low: $0.33 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -4.93% -9.57% 12 Week -13.19% -19.75% Year To Date -29.53% -35.87%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 165 LUDLOW AVENUE - NORTHVALE,NJ 07647 USA ph: 201-750-2646 fax: 201-750-2755 dianne@elitepharma.com http://www.elitepharma.com

• General Corporate Information    Officers Nasrat Hakim - Chief Executive Officer Carter Ward - Chief Financial Officer Barry Dash - Director Jeffrey Whitnell - Director Davis Caskey - Director Peer Information Elite Pharmaceuticals Inc. (GSAC) Elite Pharmaceuticals Inc. (CASIF) Elite Pharmaceuticals Inc. (ALCD.) Elite Pharmaceuticals Inc. (OMNN) Elite Pharmaceuticals Inc. (CGPI.) Elite Pharmaceuticals Inc. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 28659T200 SIC: 2834 Fiscal Year Fiscal Year End: March Last Reported Quarter: 12/01/25 Next Expected EPS Date: 06/29/26 Share - Related Items Shares Outstanding: 1,077.14 Most Recent Split Date: (:1) Beta: 0.40 Market Capitalization: $372.15 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 06/29/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: 34.55 PEG Ratio: - Price Ratios Price/Book: 4.63 Price/Cash Flow: 20.14 Price / Sales: 2.66 EPS Growth vs. Year Ago Period: 200.00% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: 119.92% vs. Previous Quarter: -13.03% ROE 03/31/26 - - 12/31/25 - 47.93 09/30/25 - -0.72 ROA 03/31/26 - - 12/31/25 - 25.81 09/30/25 - -0.35 Current Ratio 03/31/26 - - 12/31/25 - 7.34 09/30/25 - 8.04 Quick Ratio 03/31/26 - - 12/31/25 - 5.44 09/30/25 - 6.34 Operating Margin 03/31/26 - - 12/31/25 - 20.79 09/30/25 - -0.29 Net Margin 03/31/26 - - 12/31/25 - 30.98 09/30/25 - 11.33 Pre-Tax Margin 03/31/26 - - 12/31/25 - 39.42 09/30/25 - 19.32 Book Value 03/31/26 - - 12/31/25 - 0.07 09/30/25 - 0.06 Inventory Turnover 03/31/26 - - 12/31/25 - 3.48 09/30/25 - 3.15 Debt-to-Equity 03/31/26 - - 12/31/25 - 0.05 09/30/25 - 0.06 Debt-to-Capital 03/31/26 - - 12/31/25 - 4.50 09/30/25 - 5.97

Powered by Zacks Investment Research ©